PAC-14028 completed a Phase II clinical trial for the topical treatment of pruritus, rosacea, and atopic dermatitis (ClinicalTrials.gov: NCT02052531, NCT02052999 and NCT02583022, respectively).568 In 2019, the results of the clinical Phase IIb trial of PAC-14028 cream met safety and efficacy metrics.569 In addition to the TRPV1 antagonists mentioned above, numerous chemical, biological and natural agents, including NEO-6860, JNJ-39439335 and others, have been introduced in clinical trials. The gene discussed is TRPV1; the disease is Pruritus.